Escalating Plasmodium falciparum K13 marker prevalence indicative of artemisinin resistance in southern Rwanda

In 2023, we updated data collected since 2010 on and drug resistance markers in Huye district, southern Rwanda. Artemisinin resistance-associated markers occurred in 17.5% of 212 malaria patients (561H, 9.0%; 675V, 5.7%; and 469F, 2.8%), nearly double the frequency from 2019. N86, linked with lumefa...

Full description

Saved in:

Bibliographic Details
Published in:	Antimicrobial agents and chemotherapy Vol. 68; no. 1; p. e0129923
Main Authors:	van Loon, Welmoed, Schallenberg, Emma, Igiraneza, Clement, Habarugira, Felix, Mbarushimana, Djibril, Nshimiyimana, Fabian, Ngarambe, Christian, Ntihumbya, Jean Baptiste, Ndoli, Jules Minega, Mockenhaupt, Frank P
Format:	Journal Article
Language:	English
Published:	United States American Society for Microbiology 10-01-2024
Subjects:	Antimalarials - pharmacology Antimalarials - therapeutic use Antimicrobial Chemotherapy Artemisinins - pharmacology Artemisinins - therapeutic use Drug Resistance - genetics Epidemiology and Surveillance Humans Lumefantrine - therapeutic use Malaria, Falciparum - drug therapy Malaria, Falciparum - epidemiology Plasmodium falciparum - genetics Prevalence Protozoan Proteins - genetics Protozoan Proteins - therapeutic use Rwanda - epidemiology Rwanda artemisinin Plasmodium falciparum malaria Rwanda multi drug resistance
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In 2023, we updated data collected since 2010 on and drug resistance markers in Huye district, southern Rwanda. Artemisinin resistance-associated markers occurred in 17.5% of 212 malaria patients (561H, 9.0%; 675V, 5.7%; and 469F, 2.8%), nearly double the frequency from 2019. N86, linked with lumefantrine tolerance, was close to fixation at 98%. In southern Rwanda, markers signaling resistance to artemisinin and lumefantrine are increasing, albeit at a relatively slow rate.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The authors declare no conflict of interest.
ISSN:	0066-4804 1098-6596
DOI:	10.1128/aac.01299-23